Author: Anneliese

The recent convertible bond issue by Telix Pharmaceuticals shines a light on the ongoing reopening of equity capital markets (ECM), driven by positive fundamentals on the equity side along with improved sentiments for growth-related investments. This deal highlights how companies are capitalising on favourable market conditions, raising funds while keeping risk in check. As made possible through the use of hedging strategies orchestrated by J.P. Morgan, this is consistent with a broader increase in hybrid issuance ahead of an ECM recovery.

Market Conditions

Recent equity market performance has been supportive of capital raising, and JPMorgan’s arrangement of a $US550 million convertible bond is indicative of improving conditions. The strength in growth and healthcare equities helps set the backdrop for a more constructive issuance environment, particularly for equity-linked products. Telix’s share price has materially outperformed over the past 6-12 months as driven by its progress in its radiopharmaceutical pipeline, reflecting growing confidence in its commercial trajectory and broader investor appetite for healthcare innovation. This combination of equity strength and moderate volatility is particularly conducive to convertible structures, which benefit from both elevated underlying prices and option value.

The Convertible Structure

The convertible structure reflects a trade-off between capital efficiency and delayed dilution. For Telix, it provides access to funding at a lower cost than straight debt while deferring equity dilution through the conversion feature.

From an investor perspective, the asymmetric risk-reward ratio offers a more balanced risk-return profile. The equity-like potential for upside combined with downside protection inherent in bonds and three-year put adds significant value when the investing environment becomes selective and valuation-oriented.

Moreover, convertibles naturally fit the biotech industry, where the stories behind companies are powerful and potentially volatile, and the preference of investors lies in maintaining certain optionality.

Investor Participation

The investor behaviour in this issuing points to a continued appetite for high-quality growth exposure within the healthcare sector. The use of convertible bonds does suggest that despite this appetite, investors are still risk-aware and selective in their instruments, as a balancing act for capital preservation in hand with growth participation.

The Bigger Picture

Telix’s convertible bond issuance aligns with to global shift of hybrid securities bridging the gap between debt and equity in a recuperating issuance environment. Convertibles are stepping back into the spotlight as a core financing option following a subdued ECM setting in 2023 and 2024. Convertibles are an opportunity to optimise the cost of capital while preserving upside participation. Equity-linked issuance tends to recover earlier in this cycle, which may support a gradual improvement in conditions for broader ECM activity with follow-ons and IPOs over time.

https://www.afr.com/markets/equity-markets/asx-to-rise-oil-rallies-as-wall-street-hopes-for-iran-talks-20260414-p5znlz

https://www.asx.com.au/blog/listed-at-asx/asx-capital-markets-2025-year-in-review-and-2026-outlook

https://www.afr.com/street-talk/fundies-feast-on-telix-pharmaceuticals-block-amid-us550m-convertible-20260414-p5znwh

6 November 2022

When COVID-19 emerged in late 2019, it was framed primarily as a respiratory illness. Often described as “mild” for most who contracted it. But as months passed, thousands of patients began documenting persistent, debilitating symptoms that refused to resolve. Across blogs, social media threads, and online support groups, a new pattern of illness took shape; one that medicine had not yet named. From this collective testimony emerged “Long Covid”, which was not simply a post-viral complication, but arguably the first major illness to be publicly defined before it was professionally recognised. In doing so, Long Covid marked a defining moment in consumer-driven health knowledge, challenging how healthcare systems respond to uncertainty, and who gets to define disease itself.

How did the diagnosis and lived experience of Long Covid as a contested illness, one that does not fit neatly within established medical or social definitions, manifest in ways that enabled patients to advocate successfully for its medical acknowledgement?

Contested illness refers to one that does not fit well into medical or social definitions. In today’s digital landscape, these ambiguities increasingly play out online before they are resolved clinically.

Through the permeation of subjective illness experiences into professional medical dialogues, the evidence-based activism of social media users experiencing long Covid contributed to its medical recognition, informing areas of missing knowledge about the illness and COVID-19 itself. To document experiences with COVID-19 complications, many users expanded to Twitter to find other people who may have similar experiences under the hashtag #LongCovid, or on websites such as LongCovidSOS. By sharing symptoms like headaches, brain fog, and breathlessness, sufferers named their condition “Long Covid,” turning isolated experiences into a collective illness identity.

Momentum built quickly. Individual stories became patterns, and lived experience became signal. Before formal recognition, patient reports functioned as early evidence, filling gaps in medical knowledge about COVID-19’s long-term effects. Long Covid became a powerful example of how subjective illness can push into and reshape medical authority when sufferers unite and make themselves heard.

Online, patients did more than share symptoms. With access to research, medical literature, and peer discussion, they adopted clinical language in real time. The boundary between lay and expert blurred. This “lay expert” dynamic allowed lived experience to intersect directly with biomedical frameworks.

Healthcare professionals with Long Covid played a crucial bridging role. They translated symptom clusters into clinical terms while validating patient accounts. Digital spaces became sites of co-production, where patients and clinicians collectively shaped recognition.

When compared to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), the contrast is telling. Despite similar symptoms, ME/CFS lacked the same digitally networked, time-sensitive mobilisation, showcasing how infrastructure matters. A connected consumer health ecosystem accelerated Long Covid’s legitimacy.

Ultimately, Long Covid shows how illness recognition now operates in digital public spheres. Aggregated experience becomes data. Data influences research, policy, and care. In a platform-driven health landscape, the issue is no longer whether lived experience counts, but how it is structured, validated, and integrated into medicine.